logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Collaboration between the healthcare system and the pharmaceutical industry, key for Spain to consolidate its leadership in clinical trials

Representatives of the Spanish Medicines Agency, patient associations, hospitals and the pharmaceutical industry debate in a webinar on how to promote clinical research in Spain
Measures forced by the pandemic such as sending medication to the home or monitoring trials remotely, possible advances for the future

Promote clinical research in primary care and in the CCAA with less activity, among the opportunities to continue advancing

Source: www.farmaindustria.es

Spain is a reference country for conducting clinical trials of new drugs, as has been demonstrated in the research effort deployed to deal with the current coronavirus pandemic. This was revealed in the webinar “How to promote research in Spain”, which brought together representatives of patient associations, hospitals, the Spanish Agency for Medicines and the pharmaceutical industry on Tuesday at a meeting organized by the New Medical Economics magazine with the collaboration of Farmaindustria.

It was highlighted that currently in Spain there are 82 clinical trials underway on the efficacy of drugs against Covid-19 and up to a hundred other observational studies on the disease. “These figures place our country in the leading group of clinical trials on coronaviruses worldwide and confirms the fact that Spain has long been a world reference country in clinical research,” said Amelia Martín Uranga, head of the Platform of Pharmaceutical Industry Innovative Medicines. “This very high number of trials against Covid-19 has been possible thanks to the work and agility of the Spanish Medicines Agency,” he explained, to the public commitment to research and to the role of numerous pharmaceutical companies established in our country that they coordinate these trials or collaborate in others of public initiative, providing the necessary medication.

In fact, today up to one in three of the clinical trials carried out in Europe with new drugs has Spanish participation. “This leap in medical research has been possible thanks to the existence of a solid healthcare system; the prestige of Spanish researchers and doctors; administrations and an industry committed to R&D, and patient organizations increasingly involved, “said Martín. “In any case,” she added, “in a context of strong international competition, we have to think of new strategies to maintain and, where appropriate, strengthen Spain’s progress in this area.”

The meeting was also attended by María Antonia Serrano, head of Clinical Trials of the Spanish Agency for Medicines and Health Products (Aemps); José Soto, managing director of the Hospital Clínico San Carlos, Madrid, and Carina Escobar, president of the Platform of Patient Organizations. The participants highlighted the fact that Spain was the first European country to apply a large part of the new European regulation on clinical trials thanks to the entry into force of the new Royal Decree on Clinical Trials of 2015. The role of the Spanish Registry of Clinical Trials (REEC), which allows the identification of all clinical trials launched in Spain since 2013, with information on participating promoters and centers and which encourages collaborations between researchers and promoters, as well as greater information for patients.

Opportunity to attract investment

During the talk, the opportunity for Spain to be in this privileged position in carrying out these tests was revealed. “In this health crisis, the need to bet on sectors that generate knowledge has been seen, and investment in research can provide us with that leap in quality to improve our patient care and also attract investment to our country in the field of R + D, a fact that may also be essential to reactivate our economy, “said Martín.

The participants agreed to highlight that some of the changes that have occurred during these months in the conduct of clinical trials due to the pandemic, such as the delivery of medication to patients’ homes or remote monitoring of trials with verification of Source data is a step in the right direction and some of these measures may continue to be in place after the health crisis.

In this sense, some of the opportunities that Spain has to continue consolidating its international reference role in clinical research were put on the table, such as the promotion of research in primary care (vaccines and phases III of some pathologies); the commitment to testing in autonomous communities that are currently below what would correspond to them; attracting more initial phases of trials (a greater challenge for researchers and more options for early access to the drug by patients); more adaptive tests (with flexible designs, more typical of precision medicine), and reinforce qualitative and quantitative metrics that help to identify areas for improvement, to be more predictable and to gain in competitiveness. In short, Spain is prepared to respond to the scientific and organizational challenges that have become apparent in recent weeks, it is all a matter of commitment and intensifying collaboration between public and private initiative.

At Distefar we believe that close collaboration between the healthcare system and the pharmaceutical industry is essential to promote clinical research in Spain.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.